Back to News
Oct 6, 2025 12:40 PM

Gilead Reaches Settlement To Block Biktarvy Generics Until 2036

Gilead Sciences, Inc. (NASDAQ:GILD) on Monday entered into settlement agreements to resolve the patent litigations with Lupin Ltd., Cipla Ltd. and Laurus Labs Ltd., generic manufacturers that filed abbreviated new drug applications with the U.S. Food and Drug Administration to market generic versions of Biktarvy.

GILD stock is showing positive momentum. See what is happening here.

Under the agreements, no generic entry is expected before April 1, 2036, in the U.S. for Biktarvy tablets containing bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg).

Also Read: Gildea’s ...